Applications of a muscle relaxant (tolperizone) in clinical practice
Open Access
- 12 August 2021
- journal article
- research article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 52-59
Abstract
Tolperizone is a central type of muscle relaxant that is widely used in clinical practice for the treatment of patients with acute and chronic nonspecific lower back pain(LBP), inflammatory and degenerative-dystrophic joint diseases, and is used in the treatment of myofascial pain syndrome (MPS).The Russian market widely used drug tolperizone, which is comparable in its clinical and anti-inflammatory activity with the original tolperizone, as well as with non-steroidal anti-inflammatory drugs (NSAIDs). Tolperizone is prescribed mainly in complex therapy, as well as as monotherapy.In some studies, based on the clinical efficacy of tolperizone (200 mg 3 times a day), it is concluded that tolperizone can be considered as a promising treatment for acute muscle spasm, without causing drowsiness. In the treatment of pain syndromes and osteoarthritis (OA) of various localization, the optimal dosage regimen of tolperizone is currently recommended: oral 150-300 mg per day for a course of 14 days, or according to a 2-stage scheme of administration, first intramuscularly 1.0 ml 2 times a day for 5 injections, then switching to oral administration of 150 mg 3 times a day; with MPS, a single local intramuscular injection of tolperizone is prescribed at the trigger point. The addition of tolperizone (150 mg/s) to the scheme of complex therapy allows to achieve an earlier clinical effect in OA of the hip and ankle joints, suppressing further progression of the disease. When included in the therapy regimen of tolperizone (150 mg/s, 14 days) OA of the ankle joint, with ultrasound examination, there is a statistically significant decrease in the signs of synovitis.Keywords
This publication has 23 references indexed in Scilit:
- Chemoreactome analysis of tolperisone, tizanidine, and baclofen molecules: anticholinergic, antispasmodic, and analgesic mechanisms of actionNeurology, Neuropsychiatry, Psychosomatics, 2018
- Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP)Neurology, Neuropsychiatry, Psychosomatics, 2018
- Results of the post-registration clinical study “PARUS” on efficiency and safety assessment of Mydocalm-Richter for local injection therapy of a myofascial trigger zoneTerapevticheskii arkhiv, 2018
- Comparative study of therapeutic response to baclofen vs tolperisone in spasticityBiomedicine & Pharmacotherapy, 2017
- Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back painS.S. Korsakov Journal of Neurology and Psychiatry, 2017
- Management of patients with acute lumbodynia and lumbar ischialgia in outpatient settingsMeditsinskiy sovet = Medical Council, 2016
- Acute toxicity profile of tolperisone in overdose: Observational poison centre-based studyClinical Toxicology, 2015
- New insights into the use of currently available non-steroidal anti-inflammatory drugsJournal of Pain Research, 2015
- The results of the multicenter pharmaco-epidemiological observational project on the use of mydocalm in the treatment of pain syndromes with the muscle spasmS.S. Korsakov Journal of Neurology and Psychiatry, 2015
- Basic Aspects of the Pharmacodynamics of Tolperisone, A Widely Applicable Centrally Acting Muscle RelaxantThe Open Medicinal Chemistry Journal, 2014